Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Endocrine 1

Conditions

Neoplasms 3Carcinoma, Non-Small-Cell Lung 2Stomach Neoplasms 1Ovarian Neoplasms 1Esophageal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Adrenocortical Carcinoma 1

Interventions

pembrolizumab 40Cisplatin 25Fluorouracil 24Paclitaxel 21Oxaliplatin 16Capecitabine 12Leucovorin 10Irinotecan 10Docetaxel 10Gemcitabine 8Carboplatin 7atezolizumab 6Nivolumab 6Bevacizumab 6Trastuzumab 5Ramucirumab 5Radiotherapy 5spartalizumab 4Albumin-Bound Paclitaxel 4zanidatamab 3tisotumab vedotin 3patritumab deruxtecan 3lenvatinib 3fludarabine 3durvalumab 3Radiation 3Drug Therapy 3Cyclophosphamide 3130-nm albumin-bound paclitaxel 3zimberelimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Esophageal Neoplasms × N-Ac-CHAVC-NH2 × Clear all
NCT00264433 2007-08-06

A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent

Adherex Technologies, Inc.

Phase 2 Completed
EndocrineGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Esophageal Neoplasms, Carcinoma, Hepatocellular, Neoplasms, Stomach Neoplasms, Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡